Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Jun;12(2):105-109.
doi: 10.1016/j.hemonc.2019.01.002. Epub 2019 Mar 2.

Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years

Curtis Lachowiez  1 , Rachel J Cook  2 , Brandon Hayes-Lattin  2 , Richard T Maziarz  2 , Uma Borate  2 , Elie Traer  2 , Jessica Leonard  2 , Laura Newell  2 , Kim-Hien Dao  2 , Gabrielle Meyers  2
Affiliations
Free article
Clinical Trial

Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years

Curtis Lachowiez et al. Hematol Oncol Stem Cell Ther. 2019 Jun.
Free article

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is an integral therapy for patients with hematological malignancies, myelodysplasia, and bone marrow failure. Its use has been increasing over the past decade, as understanding of the treatment and its related toxicities has led to changes in patient selection, conditioning regimens, and post-transplant care. Older (age ≥65 years) patients are often considered unfit for transplantation; however, more recent data suggest that older patients, when selected appropriately, tolerate transplantation well. We report our institutional experience with HSCT in patients aged ≥70 years. A cohort of 22 patients underwent HSCT. Median overall survival was 5.16 years [95% confidence interval (CI): 1.5-8.7 years], and median post-transplant survival was 2.2 years (myelodysplastic syndrome: median 1.3 years, 95% CI: 4.7 months-2.2 years; acute myeloid leukemia: median not reached). Thirty-day mortality following HSCT was 9.5% (n = 2). These data provide further support for the use of HSCT in selected older patients, and highlight the impact of HSCT on overall survival among a patient cohort primarily of acute myeloid leukemia and myelodysplasia.

Keywords: Acute Myeloid Leukemia; Allogeneic Stem Cell Transplant; Bone Marrow Transplant; FLT-3; Hypomethylating agent; Induction Chemotherapy; Leukemia; Myelodysplastic syndrome; Targeted therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

Publication types

LinkOut - more resources